Hepatitis B e antibody; Anti-HBs: Hepatitis B surface antibody; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen. Jia-Horng Kao, Hepatitis Research Center, National Taiwan ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine.

a monoclonal antibody. Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward ...

All students must have a series of three Hepatitis B vaccinations (0, 1, and 6 months), and a post-vaccine surface antibody titer (to demonstrate immunity). The earliest the antibody titer can be ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

About Brelovitug (also known as BJT-778) Brelovitug is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B ...